
|Videos|October 2, 2020
Bayer discusses relevant clinical study results
Author(s)Modern Retina Staff Reports
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Advertisement
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The gene therapy shift: A closer look at the science powering next-generation retinal treatments
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
How European clinicians are revolutionizing retina care
4
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
5











































